Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308. https://doi.org/10.1200/jco.2013.51.4489

Article  CAS  PubMed  Google Scholar 

Rosen VM, Guerra I, McCormack M et al (2017) Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer 27:1237–1246. https://doi.org/10.1097/igc.0000000000001000

Article  PubMed  PubMed Central  Google Scholar 

Tewari KS, Sill MW, Penson RT et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654–1663. https://doi.org/10.1016/s0140-6736(17)31607-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436. https://doi.org/10.1038/nrc1369

Article  CAS  PubMed  Google Scholar 

Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82:40–50. https://doi.org/10.1016/j.critrevonc.2011.04.009

Article  PubMed  Google Scholar 

Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the california, chicago, and princess margaret hospital phase II consortia. J Clin Oncol 26:76–82. https://doi.org/10.1200/jco.2007.12.1939

Article  CAS  PubMed  Google Scholar 

Sánchez-Muñoz A, Mendiola C, Pérez-Ruiz E et al (2010) Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Oncology 79:98–104. https://doi.org/10.1159/000320602

Article  CAS  PubMed  Google Scholar 

Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC, Neubauer NL (2013) The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol 24:258–264. https://doi.org/10.3802/jgo.2013.24.3.258

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spiliopoulou P, Hinsley S, McNeish IA, Roxburgh P, Glasspool R (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. Int J Gynecol Cancer 31:1037–1044. https://doi.org/10.1136/ijgc-2021-002467

Article  PubMed  Google Scholar 

Attianese D, Massobrio R, Giorgi M et al (2024) Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients. Arch Gynecol Obstet 310(4):2183–2190. https://doi.org/10.1007/s00404-024-07670-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alagkiozidis I, Lozano M, Devraj M, Lee YC, Abulafia O (2015) Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer. Gynecol Oncol Rep 12:23–26. https://doi.org/10.1016/j.gore.2014.12.004

Article  PubMed  PubMed Central  Google Scholar 

Isono-Nakata R, Tsubamoto H, Ueda T, Inoue K, Shibahara H (2018) Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases. Gynecol Oncol Rep 24:57–60. https://doi.org/10.1016/j.gore.2018.04.001

Article  PubMed  PubMed Central  Google Scholar 

Isono-Taniguchi R, Goto M, Takimoto Y et al (2022) Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study. Gynecol Oncol Rep 42:101013. https://doi.org/10.1016/j.gore.2022.101013

Article  PubMed  PubMed Central  Google Scholar 

. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Published: November 27, 2017

Ferrero A, Fuso L, Tripodi E et al (2017) Ovarian cancer in elderly patients: patterns of care and treatment outcomes according to age and modified frailty index. Int J Gynecol Cancer. https://doi.org/10.1097/igc.0000000000001097

Article  PubMed  Google Scholar 

Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV (2023) Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res 29:30–39. https://doi.org/10.1158/1078-0432.Ccr-22-1366

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghiringhelli F, Menard C, Puig PE et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother CII maggio 56(5):641–648

Article  CAS  Google Scholar 

Zsiros E, Lynam S, Attwood KM et al (2021) Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol 7:78–85. https://doi.org/10.1001/jamaoncol.2020.5945

Article  PubMed  Google Scholar